New
ARA 290 (Cibinetide)
39,99 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Significant improvement in symptoms of small-fiber neuropathy, including pain and autonomic function.
- Anti-inflammatory action without immunosuppression.
- Microvascular endothelial protection and improved tissue perfusion.
- Neuroprotection in cases of ischemic and diabetic neuropathy.
- No hematopoietic effects; suitable for long-term use.
Description
ARA 290 (Cibinetide)
Neuroprotection / Anti-inflammatory
MECHANISM OF ACTION
A non-erythropoietic EPO-derived peptide. It selectively activates the innate repair receptor, the IRR/common β-receptor complex, without activating the classic EPO receptor homodimer. Downstream, it reduces NF-κB, upregulates the Nrf2 antioxidant response, promotes the bioavailability of nitric oxide, and modulates the regeneration of small-diameter nerve fibers.
KEY BENEFITS
- Significant improvement in symptoms of small-fiber neuropathy, including pain and autonomic function.
- Anti-inflammatory action without immunosuppression.
- Microvascular endothelial protection and improved tissue perfusion.
- Neuroprotection in cases of ischemic and diabetic neuropathy.
- No hematopoietic effects; suitable for long-term use.
SIDE EFFECTS AND SAFETY
Well tolerated in clinical trials. Mild reactions at the injection site. No erythropoietic stimulation.
RESEARCH AND CLINICAL NOTES
Phase II trial in small-fiber neuropathy associated with sarcoidosis: significant reduction in pain and improvement in corneal nerve density compared with placebo. Improvement in autonomic function demonstrated in cohorts with diabetic neuropathy.
TARGET PROFILE:
Protocols for neuropathy, programs for managing diabetic complications, and specialized practices in autoimmune or inflammatory diseases.
Additional information
| Weight | ,26 kg |
|---|
Related products
New
BPC 5 mg + TB 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
New
Epithalon
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Telomere elongation and cellular longevity.
- Epigenetic rejuvenation markers in aged tissues.
- Normalization of the circadian rhythm through pineal regulation.
- Cancer Prevention: Tumor-Suppressing Activity in Animal Models.
- Improved skin elasticity, vision, and neuroendocrine function in longevity studies.
- One of the most widely studied anti-aging peptides worldwide.
Ipamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A clean GH surge with no side effects associated with cortisol or prolactin.
- Increased lean muscle mass and fat loss.
- Improved sleep quality and recovery.
- Regulation of intestinal motility, with application in ileus.
- Ideal for long-term use due to its selectivity profile.
- Reference for use in combination with CJC-1295 without DAC.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
PT-141
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sexual desire in men and women.
- Improvement of erectile function via the central nervous system.
- Approved by the FDA for HSDD in premenopausal women as Vyleesi.
- Effective in patients who do not respond to PDE5 inhibitors.
- It can be used as needed, 45–90 minutes before the activity.
New
Semax
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Cognitive improvement: memory, attention, and processing speed.
- Neuroprotection in stroke, traumatic brain injury, and cerebral ischemia.
- Upregulation of BDNF/NGF for neuroplasticity.
- Anxiolytic and antidepressant properties.
- Immune modulation.
- Excellent safety profile: non-addictive and with minimal side effects.
New
Thymosin Alpha-1
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of T-cell immunity in immunocompromised patients.
- Reduction of viral load in hepatitis B and C.
- Adjunctive use in HIV, cancer immunotherapy, and sepsis.
- Improving the immune response to vaccines in older adults.
- Anti-inflammatory action through immune balance and Th1/Th2 regulation.
- Adjunctive use in COVID-19, with significant evidence from China and Italy.
New
Tirzepatide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
Natural Supplements and Vitamins
Nutrition and Fitness
Beauty and Personal Care
Joint and Muscle Health
Digestive Health and Detox
Immune System
Women’s and Men’s Health
Natural Energy and Antioxidants
Cardiovascular Health
Obesity & Metabolism
